FN3: a new protein scaffold reaches the clinic

Drug Discovery Today

Volumn 14, Issue 19-20, 2009, Pages 949-955

  Bloom, Laird ^a   Calabro, Valerie ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CERTOLIZUMAB PEGOL; CT 322; FIBRONECTIN; FIBRONECTIN TYPE 3; IRINOTECAN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SCREENING; GENE MUTATION; GLIOBLASTOMA; HUMAN; MOLECULAR LIBRARY; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; SOLID TUMOR; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CENTRAL NERVOUS SYSTEM NEOPLASMS; FIBRONECTINS; GLIOBLASTOMA; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PEPTIDE LIBRARY; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 70349314669     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.06.007     Document Type: Review

References (48)

1. Koide A., et al. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284 (1998) 1141-1151
2. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr. Opin. Biotechnol. 18 (2007) 295-304
3. Gebauer M., and Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr. Opin. Chem. Biol. 13 (2009) 1-11
4. Gill D.S., and Damle N.K. Biopharmaceutical drug discovery using novel protein scaffolds. Curr. Opin. Biotechnol. 17 (2006) 653-658
5. Fraser J.S., et al. Ig-like domains on bacteriophages: a tale of promiscuity and deceit. J. Mol. Biol. 59 (2006) 496-507
6. Dickinson C.D., et al. Crystal structure of the tenth type III cell adhesion module of human fibronectin. J. Mol. Biol. 236 (1994) 1079-1092
7. Litvinovich S.V., and Ingham K.C. Interactions between type III domains in the 110 kDa cell-binding fragment of fibronectin. J. Mol. Biol. 248 (1995) 611-626
8. Cota E., et al. The folding nucleus of a fibronectin type III domain is composed of core residues of the immunoglobulin-like fold. J. Mol. Biol. 305 (2001) 1185-1194
9. Wang X., et al. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science 310 (2005) 1159-1163
10. Somers W., et al. The x-ray structure of a growth hormone-prolactin receptor complex. Nature 372 (1994) 478-481
11. Gilbreth R.N., et al. A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces. J. Mol. Biol. 381 (2008) 407-418
12. D of a single-domain antibody. J. Mol. Biol. 373 (2007) 941-953
13. Stanfield R.L., et al. Maturation of shark single-domain (IgNAR) antibodies: evidence for induced-fit binding. J. Mol. Biol. 367 (2007) 358-372
14. Henderson K.L., et al. Structure of an IgNAR-AMA1 complex: targeting a conserved hydrophobic cleft broadens malarial strain recognition. Structure 15 (2007) 1452-1466
15. Koide A., and Koide S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 352 (2007) 95-109
16. Koide A., et al. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 1253-1258
17. Richards J., et al. Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J. Mol. Biol. 326 (2003) 1475-1488
18. Lipovsek D., et al. Evolution of an interloop disulfide bond in high-affinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J. Mol. Biol. 368 (2007) 1024-1041
19. Karatan E., et al. Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem. Biol. 11 (2004) 835-844
20. Xu L., et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem. Biol. 9 (2002) 933-942
21. Garcia-Ibilcieta D., et al. Simple method for production of randomized human tenth fibronectin domain III libraries for use in combinatorial screening procedures. Biotechniques 44 (2008) 559-562
22. Koide A., et al. High-affinity single-domain binding proteins with a binary-code interface. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 6632-6637
23. Huang J., et al. Design of protein function leaps by directed domain interface evolution. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 6578-6583
24. Getmanova E.V., et al. Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. Chem. Biol. 13 (2006) 549-556
25. Olson C.A., and Roberts R.W. Design, expression, and stability of a diverse protein library based on the human fibronectin type III domain. Protein Sci. 16 (2007) 476-484
26. Bertschinger J., and Neri D. Covalent DNA display as a novel tool for directed evolution of proteins in vitro. Protein Eng. Des. Sel. 17 (2004) 699-707
27. Hackel B.J., et al. Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J. Mol. Biol. 381 (2008) 1238-1252
28. Olson C.A., et al. mRNA display selection of a high-affinity, modification-specific phospho-IκBα-binding fibronectin. ACS Chem. Biol. 3 (2008) 480-485
29. Ishikawa F.N., et al. Label-free, electrical detection of the SARS virus N-protein with nanowire biosensors utilizing antibody mimics as capture probes. ACSNano 3 (2009) 1219-1224
30. Siggers K., et al. Conformational dynamics in loop swap mutants of homologous fibronectin type III domains. Biophys. J. 93 (2007) 2447-2456
31. Billings K.S., et al. Crosstalk between the protein surface and hydrophobic core in a core-swapped fibronectin type III domain. J. Mol. Biol. 375 (2008) 560-571
32. Batori V., et al. Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. Protein Eng. 12 (2002) 1015-1020
33. Huang J., et al. Conformation-specific affinity purification of proteins using engineered binding proteins: application to the estrogen receptor. Protein Expr. Purif. 47 (2006) 348-354
34. Parker M.H., et al. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng. Des. Sel. 18 (2005) 435-444
35. Liao H.I., et al. mRNA display of fibronectin-based intrabodies that detect and inhibit SARS-COV N protein. J. Biol. Chem. (2009) http://www.jbc.org/cgi/doi/10.1074/jbc.M901547200
36. Dutta S., et al. High-affinity fragment complementation of a fibronectin type III domain and its application to stability enhancement. Protein Sci. 14 (2005) 2838-2848
37. Han Z., et al. Accelerated screening of phage-display output with alkaline phosphatase fusions. Comb. Chem. High Throughput Screen. 7 (2004) 55-62
38. Tani P.H., et al. In vitro selection of fibronectin gain-of-function mutations. Biochem. J. X 365 (2004) 287-294
39. Lipovsek D., and Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods 290 (2004) 51-67
40. Duan J., et al. Fibronectin type III domain based monobody with high avidity. Biochemistry 46 (2007) 12656-12664
41. Camphausen, Ray et al. Adnexus. Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir. WO2008066752 (A2)
42. Koide A., et al. Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. Biochemistry 40 (2001) 10326-10333
43. Mamluk R., et al. Abstract. Proc. Am. Assoc. Cancer Res. 47 (2006) 230
44. Dineen S.P., et al. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer (2008). http://www.biomedcentral.com 10.1186/1471-2407-8-352
45. Sweeney C.J., et al. Abstract. J. Clin. Oncol. 26 20 Suppl. (2008) 2523
46. Molckovsky A., and Siu L.L. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology Meeting. J. Hematol. Oncol. (2008). http://www.jhoonline.org 10.1186/1756-8722-1-20
47. Tang L., et al. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93 (2004) 2184-2204
48. Choy E.H., et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41 (2002) 1133-1137